Quince Therapeutics, Inc. (QNCX)
US — Healthcare Sector
Automate Your Wheel Strategy on QNCX
With Tiblio's Option Bot, you can configure your own wheel strategy including QNCX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QNCX
- Rev/Share 0.0
- Book/Share 0.4229
- PB 3.3817
- Debt/Equity 0.8422
- CurrentRatio 4.0485
- ROIC -0.6172
- MktCap 65020384.0
- FreeCF/Share -0.7628
- PFCF -1.9399
- PE -1.035
- Debt/Assets 0.1461
- DivYield 0
- ROE -1.7268
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | QNCX | Oppenheimer | -- | Outperform | -- | $10 | March 24, 2025 |
News
Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026
QNCX
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Positive
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Positive
Quince Therapeutics is advancing eDSP for Ataxia-Telangiectasia, leveraging strong prior data in the 6-9 age group and an innovative AIDE platform. Recent insider buying, new analyst coverage with high price targets, and robust patent protection highlight growing confidence and upside potential. Data readout for the NEAT Phase 3 trial is scheduled for early 2026, with all patients joining the open-label extension, and cash runway aligns with expected topline results.
Read More
About Quince Therapeutics, Inc. (QNCX)
- IPO Date 2019-05-09
- Website https://www.quincetx.com
- Industry Biotechnology
- CEO Dr. Dirk Thye M.D.
- Employees 36
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.